R-(-)-2-[2-[4-[(4-chlorophenyl)benzyl]-1-piperazinyl]ethoxy]acetic acid dihydrochloride Molecular weight: C21H25ClN2O3bull;2HCl

This product is an oral selective histamine H1 receptor antagonist. It has no obvious anticholinergic and anti-5-hydroxytryptamine effects, and has a small central nervous system inhibitory effect.

This product is a central antitussive drug that can inhibit the cough center in the medulla oblongata to produce an antitussive effect. Its antitussive effect is equal to or slightly stronger than that of codeine. The general therapeutic dose does not inhibit breathing, and long-term use is non-addictive and non-tolerant. This product is well absorbed orally and takes effect within 10-30 minutes after taking the drug.

It is a selective monoamine antagonist with high affinity for 5HT2 receptors, D2 receptors, α1 and α2 receptors, and H1 receptors. Its mechanism of action in the treatment of schizophrenia is believed to be the result of a combined effect of antagonism on D2 receptors and 5HT2 receptors.

Telmisartan is a specific angiotensin II receptor (ATⅠ type) antagonist that binds to the ATⅠ receptor subtype with high affinity, has no agonist effect, and has a long-lasting selective binding. It does not inhibit human plasma renin and ion channels, nor does it inhibit angiotensin converting enzyme Ⅱ. Administration of 80 mg to humans can almost completely inhibit the increase in blood pressure caused by angiotensin Ⅱ, and the antihypertensive effect can last for more than 24 hours. The antihypertensive effect gradually becomes apparent within 3 hours after the first dose, and the maximum antihypertensive effect can be achieved in 4 weeks and long-term treatment can be maintained. Sudden interruption of treatment will not cause rebound hypertension, and the incidence of dry cough is lower than that of angiotensin converting enzyme inhibitors.